Manipal Health Enterprises IPO

The company has delivered the fastest revenue growth among India's leading hospital chains. Its revenue from operations increased at a compound annual growth rate (CAGR) of 29.41% between FY24 and FY26, rising from ₹6,171.63 crore to ₹10,335.75 crore. This strong growth reflects rising demand for its healthcare services and the success of its expansion strategy.

It is India's largest multi-specialty hospital group by bed capacity, with 13,037 licensed beds as of March 31, 2026. Operating at this scale gives the company stronger negotiating power with suppliers, helping it keep medical consumable costs under control. In FY26, these costs stood at ₹2,116.16 crore, or 20.47% of its revenue.

The company's average length of stay (the average number of days a patient remains admitted) was just 2.78 days in FY26, the lowest among its major peers. This means patients recover and are discharged sooner, allowing the hospitals to treat more people using the same capacity and generate higher revenue.

The company has a proven track record of acquiring hospitals and improving their performance. For example, after acquiring Columbia Asia in FY22, its operating profit margin (profit earned from core business operations) increased from 30.51% to 33.78% by FY26. This shows its ability to integrate acquisitions smoothly while improving profitability and reducing expansion risks.

It is the only private hospital network with a leading position in Bengaluru, Kolkata, and Pune, where it operates a total of 5,376 beds. This strong presence also attracts patients from nearby towns and districts, creating a steady flow of complex treatments that typically generate higher revenue.

The company reported a negative working capital cycle (meaning it receives cash from patients before it has to pay suppliers) of 13 days in FY26. This keeps cash flows healthy and reduces its dependence on short-term borrowing to manage day-to-day operations.

The company depends heavily on Karnataka, where it operates 19 hospitals with 6,404 beds. In FY26, it generated ₹4,795.38 crore, or 46.40% of its revenue from operations, from this single state alone. This means any major policy changes, regulatory issues, or disruptions in Karnataka could have a significant impact on its overall revenue.

The company has funded several acquisitions through borrowings, pushing its total debt to ₹10,553.43 crore as of March 31, 2026. As a result, its finance costs (interest paid on borrowings) jumped 68.85% to ₹864.29 crore in FY26, putting pressure on its net profit.

Some of the hospitals it has acquired are still reporting losses. For example, Sahyadri Hospitals posted a net loss of ₹48.53 crore during the period after its acquisition in FY26. If these businesses take longer than expected to become profitable, they could weigh on the group's overall earnings.

A large share of its business comes from six key specialties - cardiac, cancer, brain, gastroenterology (digestive system treatment), orthopedics, and kidney sciences. Together, these contributed ₹5,030.95 crore, or 64.30% of its gross inpatient revenue in FY26. If demand for these treatments slows or competition becomes stronger, the company's earnings could come under pressure.

The company's acquisition strategy has created goodwill (an accounting asset that represents the extra amount paid while acquiring a business) of ₹8,120.57 crore as of March 31, 2026. If the acquired hospitals fail to perform as expected, the company may have to record impairment charges (a reduction in the value of assets), which could lower its future profits.

Several of the company's hospitals operate on leased land, and some properties are involved in legal disputes. For example, the Governor of Odisha demanded ₹65.47 crore, alleging that a shareholding transfer violated the lease conditions of a hospital property. If such disputes remain unresolved, they could affect hospital operations.

Doctors' fees and employee benefits are the company's biggest expenses. In FY26, it spent ₹2,348.51 crore on doctors' fees and ₹1,490.04 crore on employee benefits. If competition for skilled doctors and healthcare professionals pushes salaries higher, the company's profit margins could come under pressure.